vs

Side-by-side financial comparison of PUMA BIOTECHNOLOGY, INC. (PBYI) and Strawberry Fields REIT, Inc. (STRW). Click either name above to swap in a different company.

PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $40.1M, roughly 1.9× Strawberry Fields REIT, Inc.). On growth, Strawberry Fields REIT, Inc. posted the faster year-over-year revenue change (31.5% vs 27.7%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 20.0%).

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

Strawberry Fields REIT, Inc. is a real estate investment trust focused on healthcare-related real estate assets. It owns, operates and manages skilled nursing facilities, senior living communities, and medical office buildings, primarily serving markets across the United States for healthcare providers and elderly care operators.

PBYI vs STRW — Head-to-Head

Bigger by revenue
PBYI
PBYI
1.9× larger
PBYI
$75.5M
$40.1M
STRW
Growing faster (revenue YoY)
STRW
STRW
+3.8% gap
STRW
31.5%
27.7%
PBYI
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
20.0%
STRW

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PBYI
PBYI
STRW
STRW
Revenue
$75.5M
$40.1M
Net Profit
$2.0M
Gross Margin
69.3%
Operating Margin
22.7%
52.4%
Net Margin
5.0%
Revenue YoY
27.7%
31.5%
Net Profit YoY
37.6%
EPS (diluted)
$0.26
$0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PBYI
PBYI
STRW
STRW
Q4 25
$75.5M
$40.1M
Q3 25
$54.5M
$39.7M
Q2 25
$52.4M
$37.9M
Q1 25
$46.0M
$37.3M
Q4 24
$59.1M
$30.5M
Q3 24
$80.5M
$29.5M
Q2 24
$47.1M
$29.3M
Q1 24
$43.8M
$27.8M
Net Profit
PBYI
PBYI
STRW
STRW
Q4 25
$2.0M
Q3 25
$8.8M
$2.0M
Q2 25
$5.9M
$2.0M
Q1 25
$3.0M
$1.6M
Q4 24
$1.5M
Q3 24
$20.3M
$944.0K
Q2 24
$-4.5M
$938.0K
Q1 24
$-4.8M
$746.0K
Gross Margin
PBYI
PBYI
STRW
STRW
Q4 25
69.3%
Q3 25
77.7%
Q2 25
76.5%
Q1 25
77.1%
Q4 24
76.4%
Q3 24
63.9%
Q2 24
77.4%
Q1 24
75.5%
Operating Margin
PBYI
PBYI
STRW
STRW
Q4 25
22.7%
52.4%
Q3 25
17.6%
56.6%
Q2 25
12.7%
54.5%
Q1 25
8.7%
54.1%
Q4 24
22.6%
51.5%
Q3 24
27.4%
54.4%
Q2 24
-4.6%
52.3%
Q1 24
-5.3%
51.3%
Net Margin
PBYI
PBYI
STRW
STRW
Q4 25
5.0%
Q3 25
16.2%
5.1%
Q2 25
11.2%
5.2%
Q1 25
6.5%
4.2%
Q4 24
4.8%
Q3 24
25.2%
3.2%
Q2 24
-9.6%
3.2%
Q1 24
-11.0%
2.7%
EPS (diluted)
PBYI
PBYI
STRW
STRW
Q4 25
$0.26
$0.15
Q3 25
$0.17
$0.16
Q2 25
$0.12
$0.16
Q1 25
$0.06
$0.13
Q4 24
$0.40
$0.17
Q3 24
$0.41
$0.14
Q2 24
$-0.09
$0.14
Q1 24
$-0.10
$0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PBYI
PBYI
STRW
STRW
Cash + ST InvestmentsLiquidity on hand
$97.5M
$31.8M
Total DebtLower is stronger
$22.7M
$794.7M
Stockholders' EquityBook value
$130.3M
$12.1M
Total Assets
$216.3M
$885.2M
Debt / EquityLower = less leverage
0.17×
65.64×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PBYI
PBYI
STRW
STRW
Q4 25
$97.5M
$31.8M
Q3 25
$94.4M
$19.8M
Q2 25
$96.0M
$96.3M
Q1 25
$93.2M
$42.3M
Q4 24
$101.0M
$48.4M
Q3 24
$96.7M
$29.3M
Q2 24
$96.8M
$16.1M
Q1 24
$107.2M
$15.1M
Total Debt
PBYI
PBYI
STRW
STRW
Q4 25
$22.7M
$794.7M
Q3 25
$34.0M
$779.4M
Q2 25
$45.3M
$794.1M
Q1 25
$56.7M
$715.5M
Q4 24
$68.0M
$673.9M
Q3 24
$79.3M
$584.5M
Q2 24
$90.7M
$555.0M
Q1 24
$102.0M
$560.4M
Stockholders' Equity
PBYI
PBYI
STRW
STRW
Q4 25
$130.3M
$12.1M
Q3 25
$115.3M
$14.2M
Q2 25
$104.7M
$15.5M
Q1 25
$97.1M
$19.6M
Q4 24
$92.1M
$18.2M
Q3 24
$71.1M
$12.6M
Q2 24
$48.5M
$7.4M
Q1 24
$51.0M
$7.5M
Total Assets
PBYI
PBYI
STRW
STRW
Q4 25
$216.3M
$885.2M
Q3 25
$202.9M
$880.6M
Q2 25
$194.9M
$897.3M
Q1 25
$196.2M
$834.8M
Q4 24
$213.3M
$787.6M
Q3 24
$220.7M
$661.5M
Q2 24
$205.0M
$635.9M
Q1 24
$214.1M
$634.9M
Debt / Equity
PBYI
PBYI
STRW
STRW
Q4 25
0.17×
65.64×
Q3 25
0.30×
54.70×
Q2 25
0.43×
51.26×
Q1 25
0.58×
36.47×
Q4 24
0.74×
37.09×
Q3 24
1.12×
46.34×
Q2 24
1.87×
74.61×
Q1 24
2.00×
74.81×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PBYI
PBYI
STRW
STRW
Operating Cash FlowLast quarter
$14.4M
$90.0M
Free Cash FlowOCF − Capex
$14.4M
FCF MarginFCF / Revenue
19.1%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
44.62×
TTM Free Cash FlowTrailing 4 quarters
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PBYI
PBYI
STRW
STRW
Q4 25
$14.4M
$90.0M
Q3 25
$9.7M
$20.7M
Q2 25
$14.1M
$29.8M
Q1 25
$3.6M
$19.0M
Q4 24
$15.6M
$59.3M
Q3 24
$11.0M
$11.8M
Q2 24
$1.0M
$20.6M
Q1 24
$11.2M
$2.1M
Free Cash Flow
PBYI
PBYI
STRW
STRW
Q4 25
$14.4M
Q3 25
$9.7M
Q2 25
$14.1M
Q1 25
$3.6M
Q4 24
$15.6M
Q3 24
$11.0M
Q2 24
$1.0M
Q1 24
FCF Margin
PBYI
PBYI
STRW
STRW
Q4 25
19.1%
Q3 25
17.7%
Q2 25
26.8%
Q1 25
7.7%
Q4 24
26.4%
Q3 24
13.7%
Q2 24
2.1%
Q1 24
Capex Intensity
PBYI
PBYI
STRW
STRW
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.1%
Q4 24
0.0%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
PBYI
PBYI
STRW
STRW
Q4 25
44.62×
Q3 25
1.10×
10.26×
Q2 25
2.41×
15.24×
Q1 25
1.21×
11.97×
Q4 24
40.44×
Q3 24
0.54×
12.53×
Q2 24
21.93×
Q1 24
2.85×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons